Resmed (RSMDF) Cash & Current Investments (2009 - 2026)

Resmed has reported Cash & Current Investments for 18 years, with the latest figure at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 78.03% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 78.03% YoY), and the FY2025 full-year result was $1.2 billion, up 407.4% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.7 billion, up from $1.4 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $1.7 billion in Q1 2026, with the low at $201.8 million in Q1 2022.
• Historically, Cash & Current Investments has averaged $578.8 million across 5 years, with a median of $253.2 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments decreased 24.98% — and 2025, when it soared 407.4%.
• Resmed's Cash & Current Investments stood at $253.2 million in 2022, then slipped by 16.96% to $210.2 million in 2023, then soared by 148.25% to $521.9 million in 2024, then surged by 171.5% to $1.4 billion in 2025, then increased by 17.18% to $1.7 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.7 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.